Scribd
Upload
61 views8 pages

Hyperlipidemic Agents

Hyperlipidemic agents are classified into several categories including statins, fibrates, and PCSK9 inhibitors, each with unique mechanisms of action. These agents are used for the prevention of atherosclerotic cardiovascular disease and management of various lipid disorders. It is important to consider their adverse effects, pharmacokinetics, and contraindications for safe administration.

Uploaded by

Vidhi Trivedi
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPTX, PDF, TXT or read online on Scribd
61 views8 pages

Hyperlipidemic Agents

Hyperlipidemic agents are classified into several categories including statins, fibrates, and PCSK9 inhibitors, each with unique mechanisms of action. These agents are used for the prevention of atherosclerotic cardiovascular disease and management of various lipid disorders. It is important to consider their adverse effects, pharmacokinetics, and contraindications for safe administration.

Uploaded by

Vidhi Trivedi
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPTX, PDF, TXT or read online on Scribd
You are on page 1/ 8

Hyperlipidemic Agents

• Classification, Mechanism of Action (MOA) in


Flowchart, Uses, Adverse Effects,
Pharmacokinetics, and Contraindications
Classification of Hyperlipidemic
Agents
• - **Statins (HMG-CoA Reductase Inhibitors)**
– Atorvastatin, Simvastatin
• - **Fibrates (PPAR-α Agonists)** –
Fenofibrate, Gemfibrozil
• - **Bile Acid Sequestrants** –
Cholestyramine, Colestipol
• - **Niacin (Vitamin B3)** – Nicotinic acid
• - **Cholesterol Absorption Inhibitors** –
Ezetimibe
• - **PCSK9 Inhibitors** – Alirocumab,
Mechanism of Action (MOA)
• A flowchart explaining how each class of drugs
acts to reduce lipid levels (to be added
manually).
Uses of Hyperlipidemic Agents
• - **Primary & Secondary Prevention of
ASCVD**
• - **Hypercholesterolemia (High LDL-C)** –
Statins, Ezetimibe, PCSK9 inhibitors
• - **Hypertriglyceridemia (High TGs)** –
Fibrates, Niacin, Omega-3 fatty acids
• - **Mixed Dyslipidemia** – Combination
therapy (Statins + Fibrates or Ezetimibe)
Adverse Effects
• - **Statins** – Myopathy, hepatotoxicity, GI
disturbances
• - **Fibrates** – Gallstones, myopathy
(especially with statins)
• - **Bile Acid Sequestrants** – Constipation,
bloating, decreased absorption of fat-soluble
vitamins
• - **Niacin** – Flushing, hyperuricemia,
hepatotoxicity
• - **Ezetimibe** – Diarrhea, increased liver
Pharmacokinetics
• Pharmacokinetic details are best represented
in a table (to be added manually in
PowerPoint).
Contraindications
• - **Statins** – Liver disease, pregnancy
• - **Fibrates** – Severe renal/hepatic disease,
gallbladder disease
• - **Bile Acid Sequestrants** – Bowel
obstruction, severe dysphagia
• - **Niacin** – Gout, peptic ulcers, liver
disease
• - **Ezetimibe** – Severe hepatic impairment
• - **PCSK9 Inhibitors** – Hypersensitivity
reactions
Summary
• - Hyperlipidemic agents help lower cholesterol
and triglycerides.
• - Different classes have distinct mechanisms of
action.
• - Consideration of **adverse effects,
pharmacokinetics, and contraindications** is
essential for safe use.

You might also like